UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

UCT943, a next generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria

Brunschwig, C; Lawrence, N; Taylor, D; Abay, E; Njoroge, M; Basarab, GS; Le Manach, C; ... Chibale, K; + view all (2018) UCT943, a next generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria. Antimicrobial Agents and Chemotherapy 10.1128/AAC.00012-18. (In press). Green open access

[thumbnail of Antimicrob. Agents Chemother.-2018-Brunschwig-AAC.00012-18.pdf]
Preview
Text
Antimicrob. Agents Chemother.-2018-Brunschwig-AAC.00012-18.pdf - Accepted Version

Download (1MB) | Preview

Abstract

The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as solubility and antiplasmodial potency across the parasite lifecycle, leading to the 2-aminopyrazine UCT943. The compound displayed higher asexual blood stage, transmission-blocking, and liver stage activity than MMV048 and was more potent against resistant P. falciparum and P. vivax clinical isolates. Excellent in vitro antiplasmodial activity translated into high efficacy in P. berghei and humanized P. falciparum NOD-scid IL-2Rγnull mouse models. The high passive permeability and high aqueous solubility of UCT943, combined with low to moderate in vitro intrinsic clearance, resulted in sustained exposure and high bioavailability in preclinical species. In addition, the predicted human dose for a curative single administration using monkey and dog pharmacokinetics was low, ranging from 50 to 80 mg. As a next generation Plasmodium PI4K inhibitor, the combined preclinical data suggest that UCT943 has the potential to form part of a single-exposure radical cure and prophylaxis (SERCaP) to treat, prevent and block the transmission of malaria.

Type: Article
Title: UCT943, a next generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1128/AAC.00012-18
Publisher version: http://dx.doi.org/10.1128/AAC.00012-18
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10052857
Downloads since deposit
120Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item